Byotrol PLC First US Retail Trial with Target (3364O)
17 May 2018 - 4:00PM
UK Regulatory
TIDMBYOT
RNS Number : 3364O
Byotrol PLC
17 May 2018
17(th) May, 2018
Byotrol plc
("Byotrol" or the "Company")
FURTHER PROGRESS IN THE US
MASS MARKET RETAIL TRIAL WITH TARGET
Byotrol plc, the specialist anti-microbial technology company,
is pleased to announce that it has secured its first mass market
retail trial in the US, for its 24-hour germ-kill surface sanitizer
'Byotrol24'.
The trial is due to take place over approximately 10-12 weeks at
the national retailer Target. We are expecting the trial to start
next month in approximately 10% of Target's 1,829 stores, following
which Target will decide whether it wishes to roll-out into
nationwide distribution.
This progress follows on closely from the Company having
completed individual US State product registration earlier this
month. Byotrol24 received formal approval from the US Environmental
Protection Agency in June 2017.
David Traynor, Chief Executive of Byotrol plc comments:
"This is really good news for Byotrol. Target Corporation is one
of the leading general merchandise retailers in the US and is
well-known for innovation and design; it is a perfect retail match
for our brand and an excellent first step in pursuing our US
commercialisation ambitions."
Enquiries:
David Traynor - Chief Executive, Byotrol plc 01925 742 000
David Paton - Investor Relations 07714 190 474
finnCap Ltd
020 7220 0500 (Nominated Adviser & Broker)
Geoff Nash/Kate Bannatyne - Corporate Finance
Richard Chambers - Corporate Broking
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer
of residual antimicrobial technologies, identifying, developing,
formulating and commercialising cutting-edge antimicrobial
solutions.
Our patented suite of technologies deliver powerful
broad-spectrum efficacy with residual performance optimised against
commonly occurring and industry-specific pathogens.
Founded in 2005, the Company has developed advanced
antimicrobial technologies that create easier, safer and cleaner
lives for everyone.
For more information, please go to www.byotrol.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTLLFIRELIRLIT
(END) Dow Jones Newswires
May 17, 2018 02:00 ET (06:00 GMT)
Byotrol (LSE:BYOT)
Historical Stock Chart
From Apr 2024 to May 2024
Byotrol (LSE:BYOT)
Historical Stock Chart
From May 2023 to May 2024
